GlassScriptPhysician profile
Scott J Johnson
NPI 1598739179
$24,394.29
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,390 · 2020: $17K · 2021: $139 · 2022: $87.17 · 2023: $98.76 · 2024: $16.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $13,790.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,559.16 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $516.76 | 2019-2023 | Opsumit |
| Glaxosmithkline, LLC. | $479.70 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $286.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $230.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $180.60 | 2019-2020 | |
| Grifols USA, LLC | $174.55 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.36 | 2022-2023 | Relistor |
| Philips North America LLC | $87.65 | 2019 | |
| Shire North American Group INC | $86.74 | 2019 | |
| Genzyme Corporation | $84.39 | 2019-2020 | |
| Lilly USA, LLC | $76.06 | 2019-2020 | |
| Insmed, INC. | $71.10 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.93 | 2019-2020 | |
| Genentech USA, INC. | $67.28 | 2019 | |
| Celgene Corporation | $65.60 | 2019 | |
| United Therapeutics Corporation | $56.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.73 | 2019-2020 | |
| Daiichi Sankyo INC. | $30.94 | 2019 | |
| Astellas Pharma US INC | $23.77 | 2020 | |
| Gilead Sciences, INC. | $23.10 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.43 | 2019 | |
| Csl Behring | $19.23 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.78 | 2024 | Horizant |
| Jazz Pharmaceuticals INC. | $16.34 | 2020 | |
| Circassia INC. | $15.32 | 2019 | |
| Advanced Respiratory, INC | $14.83 | 2019 | |
| La Jolla Pharmaceutical Company | $13.47 | 2019 | |
| Merck Sharp & Dohme LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.